BiotechTube

TTI-237

Phase 1Terminated
1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasms

Conditions

Neoplasms

Trial Timeline

May 1, 2005 → —

NCT ID
NCT00195247

About TTI-237

TTI-237 is a phase 1 stage product being developed by Pfizer for Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT00195247. Target conditions include Neoplasms.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms were approved

Approved (20) Terminated (2) Active (0)
✅LenvatinibEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Chlorhydrate de RopivacaineAstraZenecaApproved
✅Sitagliptin + placeboMerckApproved
✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00195325Phase 1Terminated
NCT00195247Phase 1Terminated

Competing Products

20 competing products in Neoplasms

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
AB0024Gilead SciencesPhase 1
29
852APfizerPhase 1
29
PemetrexedEli LillyPhase 2
35
IMC-3C5Eli LillyPhase 1
29
LY3295668Eli LillyPhase 1/2
32
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
LY2784544Eli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
29
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
120 mg LY2784544Eli LillyPhase 2
39
LY4337713Eli LillyPhase 1
36
pemetrexed + cisplatinEli LillyPhase 1/2
32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mgVincerx PharmaPhase 1
19
VIP236 (Q3W) + VIP236 (Q2W)Vincerx PharmaPhase 1
19
GEMZAR + ALIMTAEli LillyPhase 3
40